Clinical Significance of Atypical Glandular Cells in the Bethesda System 2001: A Comparison with the Histopathological Diagnosis of Surgically Resected Specimens

Shoji, Tadahiro; Takatori, Eriko; Takeuchi, Satoshi; Yoshizaki, Akira; Uesugi, Noriyuki; Sugai, Tamotsu; Sugiyama, Toru

doi:10.3109/07357907.2014.880453

Cited by 23 publications

(14 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As in the literature [5,6,10,11], the majority of our cases were histologically benign, and there was no significant difference between the two periods. We seem to see more endometrial cells, but the majority are benign on follow-up, and the differences are not significant.…”

Section: Introductionsupporting

confidence: 80%

“…Other studies have found that subcategorization of AGUS may give a higher yield of significant lesions in specific subgroups [11,[13][14][15] We can assume that the risk of an underlying malignant or premalignant lesion is of the same magnitude in Norway, and our current practice of follow up is justified and in compliance with international studies [10,13,15].…”

Section: Introductionmentioning

confidence: 92%

“…Follow-up histology is reported to be benign in > 50 % of cases in most studies [5,6,10,11]. According to Table 2 this would apply to both benign and malignant lesions.…”

Section: Introductionmentioning

confidence: 98%

See 2 more Smart Citations

LBC versus Conventional Pap Smear in AGUS; Do we do any better with Liquid-Based Preparations?

Listerud¹,

Tawakoli²,

MasoumahSoltani³

et al. 2019

Mathews Journal of Cytology and Histology

View full text Add to dashboard Cite

A diagnosis of AGUS is given when glandular cells of endocervical or endometrial origin (if > 45 of age) display nuclear atypia that exceeds obvious reactive changes but lack unequivocal features of adenocarcinoma in situ (ACIS) or invasive adenocarcinoma. The percentage of this diagnostic category varies considerably. The mean percentage of AGUS diagnoses in cervical cytology in Norway is 0.18% with a range of 0.06-0.48%. At Akershus University hospital (Ahus) 0.09% of cervical cytology diagnoses were AGUS in 2016. Our department changed from conventional to liquidbased slides during 2013-2014. The aim of our study was to see if the introduction of LBC had had any impact on the diagnosis of AGUS. We compared two cohorts of cervical smears: a three years cohort (2011-2013) of conventional Pap smears and a three years cohort (2014-2016) of Sure Path LBC smears. There were 82 women in the conventional Pap smear cohort (0.08%) and 95 in the Sure Path LBC cohort (0.09%) and all had histologic follow-up. There was no statistically difference in the results of the two cohorts. In conclusion, our major challenge in the diagnosis of AGUS are the cytological criteria and not our preparation method.

show abstract

Section: Introductionsupporting

confidence: 80%

Section: Introductionmentioning

confidence: 92%

See 1 more Smart Citation

LBC versus Conventional Pap Smear in AGUS; Do we do any better with Liquid-Based Preparations?

Listerud¹,

Tawakoli²,

MasoumahSoltani³

et al. 2019

Mathews Journal of Cytology and Histology

View full text Add to dashboard Cite

show abstract

“…The development of CC occurs over a number of years and its complexity presents clinical challenges in patients screening and treatment. Currently, The Bethesda System (35), which is a tool that is used to report Pap smear results for cervical cytologic diagnoses, provides useful data that allows research into the epidemiology, biology and pathology of cervical lesions; however, its diagnostic value remains poor (36). Instead, direct biopsy remains the gold standard for diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Comprehensive gene and pathway analysis of cervical cancer progression

Fang

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Cervical Cancer is one of the leading causes of cancer-associated mortality in women. The present study aimed to identify key genes and pathways involved in cervical cancer (CC) progression, via a comprehensive bioinformatics analysis. The GSE63514 dataset from the Gene Expression Omnibus database was analyzed for hub genes and cancer progression was divided into four phases (phases I-IV). Pathway enrichment, protein-protein interaction (PPI) and pathway crosstalk analyses were performed, to identify key genes and pathways using a criterion nodal degree ≥5. Gene pathway analysis was determined by mapping the key genes into the key pathways. Co-expression between key genes and their effect on overall survival (OS) time was assessed using The Cancer Genome Atlas database. A total of 3,446 differentially expressed genes with 107 hub genes were identified within the four phases. A total of 14 key genes with 11 key pathways were obtained, following extraction of ≥5 degree nodes from the PPI and pathway crosstalk networks. Gene pathway analysis revealed that CDK1 and CCNB1 regulated the cell cycle and were activated in phase I. Notably, the following terms, 'pathways in cancer', 'focal adhesion' and the 'PI3K-Akt signaling pathway' ranked the highest in phases II-IV. Furthermore, FN1, ITGB1 and MMP9 may be associated with metastasis of tumor cells. STAT1 was indicated to predominantly function at the phase IV via cancer-associated signaling pathways, including 'pathways in cancer' and 'Toll-like receptor signaling pathway'. Survival analysis revealed that high ITGB1 and FN1 expression levels resulted in significantly worse OS. CDK1 and CCNB1 were revealed to regulate proliferation and differentiation through the cell cycle and viral tumorigenesis, while FN1 and ITGB1, which may be developed as novel prognostic factors, were co-expressed to induce metastasis via cancer-associated signaling pathways, including PI3K-Art signaling pathway, and focal adhesion in CC; however, the underlying molecular mechanisms require further research.

show abstract

“…Verdoodt et al [17] conducted a meta-analysis to examine the accuracy of hrHPV testing for identifying or excluding (pre)cancerous lesions of the uterine cervix and reported that 19.8% of women with AGC were classified as CIN2+/AIS+. The prevalence of CIN2+/AIS+ was 22-48% in previous studies examining 50-100 cases of AGC, whereas 1 Japanese study reported that 87.5% of women diagnosed with AGC were classified as CIN2+/AIS+ [18]. In our study, 58.5% (24/41) of women with AGC were classified as CIN2+/ AIS+ and 91.7% (22/24) were CIN2+.…”

Section: Discussionmentioning

confidence: 49%

Significance of High-Risk Human Papillomavirus Testing for Atypical Glandular Cells on Cervical Cytology

et al. 2018

View full text Add to dashboard Cite

Objectives: The aim of this study was to evaluate the diagnostic significance of high-risk human papillomavirus (hrHPV) testing for managing women with atypical glandular cells (AGC) and to explore the distribution of hrHPV genotypes. Methods: We analyzed cytologic and histopathologic diagnoses in patients referred to our institution due to AGC or atypical squamous cells of undetermined significance (ASC-US). All patients underwent hrHPV testing and genotyping, and positive (PPV) and negative predictive values (NPV) for cervical intraepithelial neoplasia (CIN) 2 or worse [CIN2+/adenocarcinoma in situ (AIS)+] were calculated. Results: Among 41 cases previously diagnosed with AGC, 22 (53%) were classified as CIN2+ (2 squamous cell carcinomas), whereas only 2 were AIS or adenocarcinoma. Twenty-seven (65.8%) cases in the AGC group were hrHPV positive. The most frequent genotypes in both the ASC-US and AGC groups were HPV16 and HPV52. The PPV of hrHPV testing for CIN2+/AIS+ was significantly higher in the AGC than in the ASC-US group (74.1 vs. 35.0%; p = 0.0005). The NPV for CIN2+/AIS+ was significantly lower in the AGC than in the ASC-US group (74.4 vs. 100%; p = 0.0441). Conclusion: In patients with AGC, both glandular and squamous lesions must be monitored. hrHPV testing is useful for detecting CIN2+/AIS+ in AGC.

show abstract

Clinical Significance of Atypical Glandular Cells in the Bethesda System 2001: A Comparison with the Histopathological Diagnosis of Surgically Resected Specimens

Cited by 23 publications

References 18 publications

LBC versus Conventional Pap Smear in AGUS; Do we do any better with Liquid-Based Preparations?

LBC versus Conventional Pap Smear in AGUS; Do we do any better with Liquid-Based Preparations?

Comprehensive gene and pathway analysis of cervical cancer progression

Significance of High-Risk Human Papillomavirus Testing for Atypical Glandular Cells on Cervical Cytology

Contact Info

Product

Resources

About